ly resulting in adverse events. Quinupristin is a potent CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Danazol: Use caution when administering velpatasvir with danazol. Taking these drugs together may increase velpatasvir plasma concentrations, potentially resulting in adverse events. Danazol is a CYP3A4 inhibitor; velpatasvir is a substrate of CYP3A4.
Darunavir: Use caution when administering velpatasvir with darunavir. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, darunavir is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Darunavir; Cobicistat: Caution is warranted when cobicistat is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Clinical monitoring for adverse effects is recommended during coadministration. Cobicistat is an inhibitor of the transporters P-glycoprotein and breast cancer resistance protein (BCRP). Sofosbuvir is a substrate of P-gp and BCRP. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp or BCRP inhibitors. Use caution when administering velpatasvir with cobicistat. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP); cobicistat is an inhibitor of P-gp and BCRP. Cobicistat is also an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate. Use caution when administering velpatasvir with darunavir. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). In addition, darunavir is an inhibitor of the hepatic enzyme CYP3A4. Velpatasvir is a CYP3A4 substrate.
Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Avoid coadministration of velpatasvir with ritonavir. Taking these drugs together may significantly alter the plasma concentrations of velpatasvir, and increase the concentrations of ritonavir. Velpatasvir is a CYP3A4 substrate. Ritonavir is a mixed inducer/inhibitor of CYP3A4. In addition, both ritonavir and velpatasvir are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp). If these drugs are administered together, monitor for loss of antiviral efficacy and adverse effects. Caution is warranted when ritonavir is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Ritonvir is an inhibitor of the transporter P-glycoprotein (P-gp). Sofosbuvir is a substrate of P-gp. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp inhibitors; however, if these drugs are given together, consider increased monitoring for potential adverse effects. Concurrent administration of sofosbuvir with dasabuvir; ombitasvir; paritaprevir; ritonavir may result in elevated plasma concentrations of sofosbuvir. Ritonavir is an inhibitor of the breast cancer resistance protein (BCRP); dasabuvir and paritaprevir are substrates/inhibitors of BCRP, while sofosbuvir is a BCRP subs |
